Effects of Zamerovimab/Mazorelvimab on the rabies virus neutralizing antibody level in the grade Ⅲ rabies post exposure subjects
10.3760/cma.j.cn112866-20240624-00097
- VernacularTitle:泽美洛韦玛佐瑞韦单抗对狂犬病Ⅲ级暴露者狂犬病病毒中和抗体水平的影响
- Author:
Xiuqing WANG
1
;
Yongxian ZHA
;
Zhengxiong WANG
;
Ya JIANG
;
Xiangyu ZHANG
;
Jiangshu GUO
;
Jingyu LI
;
Xiaoqiang LIU
Author Information
1. 云南省疾病预防控制中心疫苗临床研究中心，昆明 650000
- Keywords:
Rabies;
Monoclonal antibody;
Neutralizing antibody
- From:
Chinese Journal of Experimental and Clinical Virology
2024;38(4):388-394
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to evaluate the immunoprotective effect of anti-rabies virus cocktail monoclonal antibody Zamerovimab/Mazorelvimab after rabies exposure.Methods:The dynamic data of rabies virus neutralizing antibody (RVNA) were analyzed in the Zamerovimab/Mazorelvimab Chinese phase Ⅲ study (clinical trial registration number: CTR20201819).Results:The full analysis set showed that RVNA geometric mean titers (GMT) on the 4 th, 8 th, 15 th, 43 rd, and 99 th day in the Zamerovimab/Mazorelvimab group were 4.413 IU/ml, 5.178 IU/ml, 17.062 IU/ml, 14.672 IU/ml, and 2.836 IU/ml, respectively, while those in the human rabies immunoglobulin (HRIG) group were 0.299 IU/ml, 0.451 IU/ml, 11.374 IU/ml, 18.063 IU/ml, and 6.769 IU/ml, respectively. The positive rates of RVNA on the 4 th, 8 th, 15 th, 43 rd, and 99 th day in the Zamerovimab/Mazorelvimab group were 99.9%, 99.6%, 100%, 100%, and 97.4%, respectively, while those in the HRIG group were 23.3%, 34.1%, 97.6%, 99.6%, and 98.4%, respectively. Conclusions:Compared with HRIG, Zamerovimab/Mazorelvimab cocktail monoclonal antibody reached the required protection level of RVNA very soon, thus effectively provided an immediate neutralizing effect of passive immunization therapies against rabies virus.
